Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Standard Biotools (LAB) Shares Repurchased (2022 - 2024)

Standard Biotools (LAB) reported Shares Repurchased of $29.4 million for Q2 2024, up 1126.62% year-over-year from $2.4 million in Q3 2023, and up 166.39% on a QoQ basis from $11.1 million in Q1 2024.

Standard Biotools (LAB) has 3 years of Shares Repurchased data on file, last reported at $29.4 million in Q2 2024.

  • Quarterly Shares Repurchased rose 1126.62% year-over-year to $29.4 million in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $29.4 million (up 109.9% YoY) and the FY2024 annual result came in at $40.5 million, up 647.88% from the prior year.
  • Shares Repurchased climbed to $29.4 million in Q2 2024 per LAB's latest filing, from $11.1 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $29.4 million in Q2 2024 and bottomed at $174000.0 in Q4 2023.
  • The 3-year median for Shares Repurchased is $2.4 million (2023), against an average of $6.6 million.
  • The widest annual swing landed in 2023, when Shares Repurchased slumped 69.09%; it then soared 1126.62% in 2024.
  • Tracing LAB's Shares Repurchased over 3 years: stood at $563000.0 in 2022, then tumbled by 69.09% to $174000.0 in 2023, then surged by 16818.97% to $29.4 million in 2024.
  • Per Business Quant, the three latest LAB Shares Repurchased figures stand at $29.4 million (Q2 2024), $11.1 million (Q1 2024), and $174000.0 (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares Repurchased (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 180.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 105.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 421.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 100.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 74.30 Mn
10 Standard Biotools 448.37 Mn -6.80 Mn 11.31 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 29.44 Mn
Jun 30, 2024 29.44 Mn
Mar 31, 2024 11.05 Mn
Mar 31, 2024 11.05 Mn
Dec 31, 2023 174,000.00
Dec 31, 2023 174,000.00
Sep 30, 2023 400,000.00
Sep 30, 2023 400,000.00
Jun 30, 2023 2.40 Mn
Jun 30, 2023 2.40 Mn
Mar 31, 2023 2.47 Mn
Mar 31, 2023 2.47 Mn
Dec 31, 2022 563,000.00
Dec 31, 2022 563,000.00